HC Wainwright Has Bullish Forecast for Agenus Q1 Earnings

Agenus Inc. (NASDAQ:AGEN) – Investment analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Agenus in a research note issued on Tuesday, March 18th. HC Wainwright analyst E. Bodnar now anticipates that the biotechnology company will post earnings of ($1.85) per share for the quarter, up from their prior forecast of ($2.29). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Agenus’ current full-year earnings is ($12.55) per share. HC Wainwright also issued estimates for Agenus’ Q2 2025 earnings at ($1.26) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.61) EPS, FY2025 earnings at ($4.37) EPS, FY2026 earnings at ($3.79) EPS, FY2027 earnings at ($3.25) EPS, FY2028 earnings at ($3.48) EPS and FY2029 earnings at ($2.32) EPS.

A number of other research firms also recently weighed in on AGEN. StockNews.com upgraded Agenus from a “sell” rating to a “hold” rating in a research report on Friday. Robert W. Baird dropped their price objective on Agenus from $6.00 to $3.00 and set a “neutral” rating for the company in a report on Wednesday, March 12th. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $8.75.

Agenus Stock Down 3.6 %

AGEN stock opened at $1.61 on Thursday. The company has a market cap of $37.77 million, a P/E ratio of -0.14 and a beta of 1.23. Agenus has a twelve month low of $1.60 and a twelve month high of $19.69. The business has a fifty day moving average of $3.01 and a 200-day moving average of $3.67.

Agenus (NASDAQ:AGEN) last released its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million for the quarter, compared to the consensus estimate of $30.09 million.

Institutional Investors Weigh In On Agenus

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Corton Capital Inc. bought a new stake in shares of Agenus in the fourth quarter worth about $36,000. Virtu Financial LLC bought a new stake in shares of Agenus in the fourth quarter worth about $51,000. Apollon Wealth Management LLC bought a new stake in shares of Agenus in the fourth quarter worth about $55,000. EP Wealth Advisors LLC bought a new stake in shares of Agenus in the third quarter worth about $55,000. Finally, Bank of Montreal Can bought a new stake in shares of Agenus in the fourth quarter worth about $69,000. Institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.